Tumour Retention of Lu-177 FAPI-2286 in Recurrent Glioblastoma – A Proof of Concept
Article History
-
Received: ,
Accepted: ,
,
Abstract
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumour. There are very few and dissatisfactory treatment options for recurrence. Ga-68 fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography provides higher tumour-to-background contrast. We present the case of a 44-year-old male with recurrent GBM who underwent a tumour retention study with Lu-177 FAPI-2286. Serial whole-body planar imaging demonstrated tumour tracer retention up to day 7 postinjection, with tumour-to-background ratios peaking at days 2–4 and remaining favourable thereafter. This case highlights the prospect of Lu-177 FAPI-2286 as a therapeutic agent in recurrent GBM.
Keywords
How to cite this article: Bishnoi K, Damle NA, Tandon V, Priyanka GB, Tripathi M, Shamim SA, et al. Tumour Retention of Lu-177 FAPI-2286 in Recurrent Glioblastoma – A Proof of Concept. Indian J Nucl Med. 2026;41:414-6. doi: 10.25259/IJNM_156_25.
A 44-year-old male with recurrent left frontoparietotemporal glioblastoma, who showed an intense fibroblast activation protein inhibitor (FAPI) avidity on Ga-68 FAPI positron emission tomography/computed tomography, underwent a low- dose (~5 mCi) Lu-177 FAPI-2286 tumour retention study to evaluate the feasibility of Lu-177 FAPI-2286 as a potential therapeutic agent. Prior ethical approval was obtained from the institute ethics committee (AIIMSA4081/24.07.2025).
This biodistribution pattern demonstrates selective and sustained localisation of Lu-177 FAPI-2286 in the glioblastoma lesion, and persistence of uptake beyond 96 h [Fig 1-4], which is favourable for effective therapy. These observations align with the feasibility and early dosimetry study of Lu-177 FAPI-2286 in various solid tumours, such as sarcomas, breast, ovary, rectum, and pancreatic adenocarcinoma.[1,2] There are also clinical reports of radionuclide therapy using Lu-177 FAPI-2286 in nasopharyngeal carcinoma, radioiodine refractory papillary thyroid carcinoma, sarcomas, and breast cancer, as well as in bone pain palliation in breast cancer patients, showing a favourable response.[3-8] Literature search revealed a single case report discussing the potential use of Lu-177 FAPI therapy in glioblastoma multiforme (GBM) using DOTAGA. Glu.(FAPi) 2 peptide.[9] Our case provides initial clinical proof that theranostics based on Lu-177 FAPI-2286 are feasible in recurrent GBM.




Theranostic techniques that target tumour stroma and cancer-associated fibroblasts may provide a fresh approach to aggressive and recurrent glioblastoma. Future treatment trials in this high-unmet-need population can be supported by the retention findings seen here.
Author contributions:
KB: Clinical input, image analysis, data curation, literature review, manuscript writing – review, editing and approval; NAD: Concept and design, clinical input, image interpretation, manuscript review and approval; AK: Clinical and surgical input, manuscript review and approval; VT: Clinical and surgical input, manuscript review and approval; GP: Clinical input, manuscript review and approval; MT: Clinical input, manuscript review and approval; SAS: Clinical input, manuscript review and approval; MSL: Imaging acquisition and technical validation of imaging data, manuscript review & approval
Ethical approval:
Institutional Review Board approval is not required.
Declaration of patient consent:
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.
Conflicts of interest:
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.
Financial support and sponsorship: Nil.
References
- Feasibility and therapeutic potential of [(177)Lu] Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52:237-46.
- [CrossRef] [PubMed] [Google Scholar]
- Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: First-in-humans results. J Nucl Med. 2022;63:415-23.
- [CrossRef] [PubMed] [Google Scholar]
- 99m Tc-FAPI-46 scintigraphy and radioligand therapy ith 177 Lu-FAPI-2286 in locally advanced epithelioid sarcoma.
- [Google Scholar]
- 99m Tc-FAPI-46 scan and 177 Lu-FAPI-2286 treatment in a patient with nasopharyngeal carcinoma. Clin Nucl Med. 2025;50:e379-80.
- [CrossRef] [PubMed] [Google Scholar]
- 177Lu-FAPI-2286 therapy in a patient with radio-iodine refractory papillary thyroid carcinoma: A favorable clinical and biochemical response. Clin Nucl Med. 2025;50:e315-6.
- [CrossRef] [PubMed] [Google Scholar]
- First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma. Clin Nucl Med. 2024;49:e334-7.
- [CrossRef] [PubMed] [Google Scholar]
- Favorable palliative effect of 177 Lu-FAPI-2286 in two breast cancer patients with refractory bone pains. Clin Nucl Med. 2025;50:e564-7.
- [CrossRef] [PubMed] [Google Scholar]
- 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE) J Nucl Med. 2022;63:2271.
- [Google Scholar]
- [(177)Lu] Lu-DOTAGA.Glu(FAPi)(2) radionuclide therapy: A new treatment option for patients with glioblastoma multiforme. Nucl Med Mol Imaging. 2024;58:32-4.
- [CrossRef] [PubMed] [Google Scholar]

